123 related articles for article (PubMed ID: 22398230)
1. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Stricklin SM; Stoecker WV; Rader RK; Hood AF; Litt JZ; Schuman TP
Dermatol Online J; 2012 Feb; 18(2):9. PubMed ID: 22398230
[TBL] [Abstract][Full Text] [Related]
2. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Tanaka K; Ogawa Y; Shimada S
J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
[No Abstract] [Full Text] [Related]
3. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
4. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin intolerance.
Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
[No Abstract] [Full Text] [Related]
6. Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Mas-Vidal A; Santos-Juanes J; Esteve-Martinez A; Caminal-Montero L; Coto-Segura P
Australas J Dermatol; 2012 Feb; 53(1):70-2. PubMed ID: 22309337
[TBL] [Abstract][Full Text] [Related]
7. [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Oct; 68(10):504-10. PubMed ID: 24298724
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
9. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Nishioka T; Shinohara M; Tanimoto N; Kumagai C; Hashimoto K
Dermatology; 2012; 224(1):20-1. PubMed ID: 22056790
[TBL] [Abstract][Full Text] [Related]
10. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
12. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Stafford S; Elahi D; Meneilly GS
J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
[No Abstract] [Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
14. Severe leucopenia associated with Sitagliptin use.
Pitocco D; Zaccardi F; Martini F; Scavone G; Musella T; Caputo S; Ghirlanda G
Diabetes Res Clin Pract; 2011 Feb; 91(2):e30-2. PubMed ID: 21035885
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
Desai S; Brinker A; Swann J; Iyasu S
Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
17. Elevated hepatic enzymes potentially associated with sitagliptin.
Gross BN; Cross LB; Foard J; Wood Y
Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
[No Abstract] [Full Text] [Related]
18. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
19. Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.
Nakai N; Katoh N
Allergol Int; 2014 Sep; 63(3):489-91. PubMed ID: 24957113
[No Abstract] [Full Text] [Related]
20. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]